At 24 weeks , the proportion of patients meeting the primary end point was 17.9 % ( 10/56 ) in the hydroxychloroquine group and 17.2 % ( 11/64 ) in the placebo group ( odds ratio , 1.01 ; 95 % CI , 0.37-2 .78 ; P = .98 ) .